| (Values in U.S. Thousands) | Feb, 2026 | Nov, 2025 | Aug, 2025 | May, 2025 | Feb, 2025 |
| Sales | 9,840 | 10,980 | 9,860 | 11,670 | 14,030 |
| Sales Growth | -10.38% | +11.36% | -15.51% | -16.82% | +23.07% |
| Net Income | -750 | -140 | -250 | 420 | 940 |
| Net Income Growth | -435.71% | +44.00% | -159.52% | -55.32% | +177.69% |
Bioqual Inc (BIOQ)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
BIOQUAL, Inc., formerly Diagnon Corporation, develops, produces and sells diagnostic test kits incorporating monoclonal antibodies to diagnose certain anemias, infections, and parasitic diseases.
Fiscal Year End Date: 05/31